We are live on
!
Find out more
Grantham, Mayo, Van Otterloo & Co (GMO) Portfolio holdings
AUM
$39.1B
1-Year Est. Return
28.69%
This Fund
S&P 500
This Quarter
Est. Return
-1.68%
1 Year Est. Return
+28.69%
3 Year Est. Return
+71.15%
5 Year Est. Return
+97.93%
10 Year Est. Return
+429.41%
AUM
$39.1B
AUM Growth
-$26.3M
(-0.07%)
Cap. Flow
+$1.59B
Cap. Flow
% of AUM
4.07%
Top 10 Holdings %
Top 10 Hldgs %
39.91%
Holding
738
New
84
Increased
295
Reduced
215
Closed
110
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mastercard
MA
|
+$499M |
| 2 |
Synopsys
SNPS
|
+$411M |
| 3 |
Microsoft
MSFT
|
+$380M |
| 4 |
Netflix
NFLX
|
+$354M |
| 5 |
Cigna
CI
|
+$177M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$546M |
| 2 |
Wells Fargo
WFC
|
+$453M |
| 3 |
PR
Permian Resources
PR
|
+$229M |
| 4 |
Elevance Health
ELV
|
+$195M |
| 5 |
NVIDIA
NVDA
|
+$97.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.72% |
| 2 | Healthcare | 23.65% |
| 3 | Communication Services | 11.87% |
| 4 | Financials | 10.29% |
| 5 | Consumer Discretionary | 8.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
601
Eastman Chemical
EMN
$7.77B
| $259K | ﹤0.01% |
3,391
| – | – |
|
|
LTC
602
LTC Properties
LTC
$2.14B
| $254K | ﹤0.01% |
+6,836
| New | +$257K |
|
603
Buckle
BKE
$2.16B
| $244K | ﹤0.01% |
+4,843
| New | +$251K |
|
604
Host Hotels & Resorts
HST
$16.4B
| $242K | ﹤0.01% |
+12,653
| New | +$241K |
|
605
Brady Corp
BRC
$4.41B
| $238K | ﹤0.01% |
2,930
-707
| -19% | -$61.5K |
|
606
ICF International
ICFI
$1.4B
| $234K | ﹤0.01% |
3,589
| – | – |
|
|
DMC
607
Del Monte Corp
DMC
$1.35B
| $233K | ﹤0.01% |
5,796
| – | – |
|
608
FNB Corp
FNB
$6.72B
| $224K | ﹤0.01% |
+13,390
| New | +$231K |
|
609
Walmart Inc
WMT
$863B
| $214K | ﹤0.01% |
1,720
-11,950
| -87% | -$1.47M |
|
|
DCH
610
Dauch Corp
DCH
$1.33B
| $212K | ﹤0.01% |
35,812
+9,537
| +36% | +$66.3K |
|
611
Pediatrix Medical
MD
$2.1B
| $207K | ﹤0.01% |
+9,692
| New | +$202K |
|
612
Costco
COST
$411B
| $207K | ﹤0.01% |
208
-1,300
| -86% | -$1.27M |
|
|
RNA
613
Atrium Therapeutics
RNA
$204M
| $206K | ﹤0.01% |
+15,444
| New | +$217K |
|
614
SunCoke Energy
SXC
$763M
| $180K | ﹤0.01% |
27,585
+12,248
| +80% | +$86.6K |
|
615
Kohl's
KSS
$2.06B
| $178K | ﹤0.01% |
13,818
-2,021
| -13% | -$34.1K |
|
616
Upwork
UPWK
$1.08B
| $159K | ﹤0.01% |
14,493
-45,326
| -76% | -$714K |
|
617
Nokia
NOK
$54.3B
| $145K | ﹤0.01% |
18,000
| – | – |
|
618
Wendy's
WEN
$1.37B
| $133K | ﹤0.01% |
+19,169
| New | +$148K |
|
619
Apple Hospitality REIT
APLE
$3.92B
| $119K | ﹤0.01% |
10,334
| – | – |
|
620
Spok Holdings
SPOK
$220M
| $114K | ﹤0.01% |
10,473
-1,834
| -15% | -$23.3K |
|
621
Vanda Pharmaceuticals
VNDA
$322M
| $113K | ﹤0.01% |
+16,322
| New | +$126K |
|
622
Orion
OEC
$387M
| $87.4K | ﹤0.01% |
+13,440
| New | +$79.5K |
|
|
ILPT
623
Industrial Logistics Properties Trust
ILPT
$613M
| $77.9K | ﹤0.01% |
13,716
| – | – |
|
624
Larimar Therapeutics
LRMR
$417M
| $58.8K | ﹤0.01% |
+13,065
| New | +$52.2K |
|
625
Holley
HLLY
$303M
| $41.3K | ﹤0.01% |
+13,457
| New | +$51K |
|
Similar funds
HF
Grantham, Mayo, Van Otterloo & Co (GMO)'s Q1 2026 Portfolio in Review
As of Q1 2026, Grantham, Mayo, Van Otterloo & Co (GMO) held 738 positions worth $39.1B, down 0.07% from $39.1B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Grantham, Mayo, Van Otterloo & Co (GMO) deployed $1.59B of net new capital in Q1 2026, opening 84 new positions and adding to 295 existing holdings. Its largest new stake was Synopsys: 910,133 shares worth $361M.
By sector, the portfolio is most concentrated in Technology at 32% of assets, down from 32% a quarter earlier, followed by Healthcare and Communication Services.
On the sell side, the largest reduction was Lam Research, an estimated $546M trimmed.
- Grantham, Mayo, Van Otterloo & Co (GMO)'s largest Q1 2026 buy was Synopsys: 910,133 shares worth $361M.
- Grantham, Mayo, Van Otterloo & Co (GMO) added most to Mastercard in Q1 2026, an estimated $499M increase.
- Grantham, Mayo, Van Otterloo & Co (GMO)'s biggest Q1 2026 reduction was Lam Research, cutting an estimated $546M.
- Grantham, Mayo, Van Otterloo & Co (GMO) fully exited Comerica in Q1 2026, selling an estimated $36.8M.
- Grantham, Mayo, Van Otterloo & Co (GMO)'s ten largest holdings make up 40% of its $39.1B portfolio in Q1 2026.
- Grantham, Mayo, Van Otterloo & Co (GMO) opened 84 new positions and closed 110 in Q1 2026.
- Grantham, Mayo, Van Otterloo & Co (GMO)'s portfolio value fell 0.07% quarter-over-quarter to $39.1B.
Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q1 2026, filed 14 May 2026.